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Abstract
The human epidermal growth factor receptor (EGFR) is an important therapeutic target in patients with metastatic
colorectal cancer and anti-EGFR antibodies cetuximab and panitumumab have been approved for the treatment of such
patients. Despite these advances, the duration of response in some patients can be limited. Since, EGFR is capable of
forming heterodimers with the other members of the HER (Human epidermal receptor) family, it is important to investigate
the co-expression and prognostic significance of all members of the HER family in colorectal cancer patients. The expression
of the HER family members were determined in tumour specimens from 86 patients with Dukes’ C and D (metastatic) colon
cancer using immunohistochemistry. Sections were scored by the percentage of positive tumour cells and intensity of
staining. Their associations with clinicopathological parameters, and overall survival and disease free survival were evaluated
using univariate and multivariate analysis. Overall, 43%, 77%, 52% and 92% of the cases were EGFR, HER-2, HER-3 and HER-4
positive respectively. Interestingly, 35%, 24%, 43%, and 18% of the cases had co-expression of EGFR/HER-2, EGFR/HER-3,
EGFR/HER-4 and all four members of the HER family respectively. Of these, only the expression of EGFR and co-expression of
EGFR/HER-4 were associated with poorer disease-free survival in both univariate and multivariate analysis. Co-expression of
all members of the HER family in colon cancer supports the need for further investigations on their predictive value for
response to therapy with anti-EGFR mAbs and whether such sub-population of patients may benefit from therapy with the
new generation of pan-HER inhibitors.
Citation: Khelwatty SA, Essapen S, Bagwan I, Green M, Seddon AM, et al. (2014) Co-Expression of HER Family Members in Patients with Dukes’ C and D Colon
Cancer and Their Impacts on Patient Prognosis and Survival. PLoS ONE 9(3): e91139. doi:10.1371/journal.pone.0091139
Editor: Hiromu Suzuki, Sapporo Medical University, Japan
Received December 11, 2013; Accepted February 7, 2014; Published March 7, 2014
Copyright:  2014 Khelwatty et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work is supported by a grant from BRIGHT cancer charity (UK). The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: H.Modjtahedi@Kingston.ac.uk
Introduction
Colorectal cancer remains one of the leading causes of cancer
deaths worldwide. In 2013, colorectal cancer is estimated to be the
fourth most commonly diagnosed cancer (142,820) but the second
leading cause of cancer deaths (50,830) after lung cancer in the
USA [1]. Currently, of the various drugs developed for the
targeted therapy of human cancers, the anti-epidermal growth
factor receptor (EGFR) monoclonal antibodies (mAbs), cetuximab
and panitumumab, and the anti-vascular endothelial growth factor
(VEGF) mAb bevacizumab have been incorporated into treatment
paradigms for the majority of patients with metastatic colorectal
cancer [2–5]. While the inclusion of these agents has improved the
survival of patients with metastatic colorectal cancer, the duration
of response can be limited. In addition, there has been no reliable
predictive marker for response to these anti-EGFR targeted
therapies [6–10]. The development and identification of such
markers not only could aid in the selection of a more specific sub-
population of colorectal cancer patients who are more likely to
benefit from such therapies, but they may also reduce unnecessary
treatments and thereby the high cost to the healthcare system [11].
In the past four decades, the aberrant expression of different
members of the HER family and their ligands have been reported
in a variety of human cancers. In some studies, these have been
associated with resistance to conventional forms of therapy and a
poorer prognosis [6,12,13]. However, there is a wide variation in
the reported expression of the HER family members in colorectal
cancer patients [6,14–16]. In addition to the formation of
homodimers, the HER family members such as the EGFR are
capable of being activated by forming heterodimers with other
members of the HER family [17–19].
While a limited number of studies have investigated the
expression and prognostic significance of individual members of
the HER family in patients with colorectal cancer [20–23],
however, to our knowledge, there have been no comprehensive
studies on the co-expression and prognostic significance of the
complete members of HER family in colorectal cancer patients to
date [6]. Therefore, in this study we have investigated the
expression levels of all members of the HER family, individually as
well as their co-expression in tumour specimens from 86 patients
with Dukes’ C and D colon cancer. We also investigated any
association between the expression of the HER family members
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and the clinicopathological parameters, disease free survival and
overall survival.
Materials and Methods
Patient Information
Ethical approval was obtained from the Research and
Development Committee of the Royal Surrey County Hospital
for examination of tumour specimens from patients with colon
cancer for use in this retrospective study. As only archived tumour
specimens were included in this study, the ethics committee
waived the need for consent and patient records/information were
analysed anonymously. Eighty-six patients with Dukes’ C and D
colon cancer, who underwent radical surgery at the Royal Surrey
County Hospital (Guildford, UK) between April 2002 and
November 2007, were included in this retrospective study. Those
with no follow-up information, mis-diagnosis, and incomplete
histology were excluded. Cases of peri- and post-operative death
were also excluded from this study, as were those with tumour
blocks in a condition too poor for immunohistochemical use.
Detailed clinicopathological information, including patient age
and gender was available for each patient.
Immunohistochemistry
Formalin fixed paraffin-embedded (FFPE) sections of tumour
specimens (3 mM) were cut in serial sections and were stained
using the following primary antibodies mouse anti-EGFR (1:10,
Novacastra, UK), mouse anti-HER-2 (1:150, Insight biotechnol-
ogy, UK), mouse anti-HER-3 (1:20, Novacastra, UK) and rabbit
anti-HER-4 (1:20, Fisher Scientific, UK). Following antigen
retrieval, tumour sections were incubated with primary antibodies
anti EGFR, HER-3 and HER-4 for 60 minutes and HER-2 for 32
minutes. Protocol optimisation was carried using established HER
positive cancer cell line pellets, namely the EGFR overexpressing
human colorectal cancer cell line DiFi, which was kindly provided
by Dr Z Fan (MD-Anderson Cancer Centre, USA), the HER-2
overexpressing human breast carcinoma cell line SKBR3 (HER-
2), and the HER-3 and HER-4 positive human breast carcinoma
cell line MCF-7 as described previously [24]. Staining was carried
out on a Venatana Benchmark XT autostainer with the ultraView
DAB kit (Roche, UK). Finally, all slides were rehydrated and
counterstained with haematoxylin, mounted and cover slipped.
Scoring System
In the current literature, the cut-off values for scoring positive
HER immunostaining of tumour sections is variable. In this study,
the immunostaining of the tumour sections were scored based on
the percentage of tumour cells that had HER immunostaining (i.e.
.5%, .10%, and .50%) and intensity of immunostaining (i.e.
negative 0, weak positive 1+, moderately positive 2+ and strongly
positive 3+) and whether the staining was predominantly present
in the membrane, cytoplasm or nucleus of the cells [15]. Of the
HER immunostaining, HER-4 had the highest levels of back-
ground staining and therefore immunostaining above the back-
ground level only was considered [22]. Two independent
observers (including a consultant histopathologist), without prior
knowledge of the clinicopathological parameters, conducted the
scoring and any disparity in scoring was resolved by simultaneous
reassessment of the staining by both observers.
Statistical Analysis
The association between immunohistochemistry scores and
patient clinicopathological data was assessed using Chi-Squared
test (Pearson Chi-Square) and Fishers exact test. Kaplan-Meier
survival plots were used to perform univariate analysis and the
differences between groups was evaluated by performing log rank-
test. For multivariate analysis, the Cox multi regression model was
used and P#0.05 was considered statistically significant. All
statistical analyses were carried out using the PASW statistics 21
(SPPS Inc.).
Results
Clinicopathological Features
Patient clinicopathological characteristics are summarised in
Table 1. The median patient follow-up time was 6 years. None of
the patients had received radiotherapy or chemotherapy prior to
surgery. Fifty-two patients received post-operative adjuvant
chemotherapy, which was predominantly 5-fluorouracil based
with some patients receiving oxaliplatin and irinotecan based
therapies. A poorer overall survival was observed in patients with
Dukes’ D compared with Dukes C (3.260.6 versus 6.260.4 years,
P= 0.005), and those with more than 3 positive lymph nodes
(4.360.4 versus 6.760.5 P= 0.008). No significant association was
found between patient outcome and the other clinicopathological
parameters (Table 1.).
Table 2. Immunohistochemical expression of HER family members in Dukes’ C and D colon cancer patients.
Scoring criteria No. of positive tumours (%)
EGFR HER-2 HER-3 HER-4
Percentage of positive tumour cells .5 37 (43) 66 (77) 45 (52) 79 (92)
.10 26 (30) 10 (12) 39 (45) 79
.50 3 (4) 7 (8) 19 (22) 79
Intensity 1+ 30 23 31 36
2+ 6 41 14 45
3+ 1 3 0 13
Sub-cellular localisation Membranous 30 5 21 24
Cytoplasmic 7 62 39 71
Luminal 0 0 31 0
doi:10.1371/journal.pone.0091139.t002
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Immunohistochemical Expression of HER Family
Members
At cut off value of $5%, tumour specimens from 43%, 77%,
52% and 92% of cases were EGFR, HER-2, HER-3 and HER-4
positive respectively (Table 2). In contrast to the EGFR, which had
predominantly membranous staining, the predominant location of
HER-2, HER-3 and HER-4 immunostaining was cytoplasmic
(Table 2 & Figure 1). In this study, we have investigated the co-
expression of all the members of the HER family in colon cancer
patients and the results are presented in Table 3. Co-expression of
EGFR with HER-2, HER-3, HER-4, and HER-2/HER-4 were
present in 35%, 24%, 43% and 76% of the cases examined
(Table 3). Interestingly, 18% of the patients in this study were
found to co-express all four members of the HER family (Table 3
& Figure 2).
Figure 1. The immunostaining ofHER familymembers inDukes’ C andD colon cancer specimens. Immunostaining of EGFR 3+, HER-2 3+, HER-
3 2+, and HER-4 3+ in formalin fixed paraffin embedded tumour sections stained immunohistochemically, as described undermethods and patients section.
Magnification:6200.
doi:10.1371/journal.pone.0091139.g001
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The percentage of HER positive colon cancer cases was also
evaluated when immunostaining was present in more than10%
and 50% of tumour cells (Table 2). Using the cut-off values of
above 10% and 50%, the percentage of cases with EGFR positive
tumours were 30% and 4%, HER-2 positive tumours were12%
and 8% and HER-3 positive tumours were 45% and 22%,
respectively (Table 2). The number of HER-4 positive tumours
remained the same regardless of the cut-off values of the
percentage of positive tumour cells, as all patients had HER-4
immunostaining in more than 50% of the tumour cells in this
study (Table 2).
Expression and Co-expression of HER Family Members is
Associated with Clinicopathological Parameters
The association between clinicopathological characteristics and
the expression of HER family members was determined by the
Chi-squared test. All sub-categories (i.e. percentage positive cells,
intensity and location of the immunostaining), which were found
to have a statistically significant association with clinicopatholog-
ical parameters are summarised in Table 4.
When immunostaining was present in greater than 5% of
tumour cells, a significant association was found between the
expression of EGFR and age (P= 0.022), and tumour site
(P= 0.022), with a significantly higher number of patients over
70 years having EGFR positive tumours in the left colon (Table 4).
In addition, a significantly higher number of Dukes’ C tumours
were found to express HER-4 (P= 0.011) (Table 4). Like EGFR
expression, the co-expression of EGFR/HER-4 was also signifi-
cantly associated with patients over 70 years old (P= 0.031) and
presenting tumours in the left colon (P=0.039) in this study. In
addition, a significantly higher number of tumours in the left colon
were found to co-express EGFR/HER-2/HER-4 (P= 0.036)
(Table 4).
At the cut off value of above 10%, the expression of HER-2 was
associated with involvement of more than 3 positive lymph nodes
(P= 0.047) (Table 4). In addition, a significantly higher number of
tumours expressing HER-3 (P= 0.037), or co-expressing EGFR/
HER-3 (P=0.035), or HER-3/HER-4 (P= 0.026) were found in
tumours ,pT4 stage in this study (Table 4). When analysed based
on the intensity of HER staining, a significant association was
found between HER-4 immunostaining intensity of 1+ and 2+ and
a higher number of G3 tumours (Table 4).
Disease-free Survival is Significantly Associated with the
Expression and Co-expression of HER Family Members
The association between the expression of individual, two,
three, or all four members of the HER family and disease-free
survival was investigated using Kaplan-Meier curves and log rank-
test. Disease-free survival was found to be significantly poorer in
patients with EGFR expression at cut off values of both above 5%
(P= 0.019) and 50% (P= 0.005), membranous expression of the
EGFR (P = 0.004) and EGFR immunostaining intensity of 1+
(P= 0.041) (Figure 3 & Table 5). In addition, there was a
significant association between the co-expression of EGFR and
HER-4 at above 5% or above 10% of tumour cells and poorer
disease-free survival (P= 0.019) (Table 5). The co-expression of
HER-2/HER-3 was also found to be significantly associated with
poorer disease-free survival (P= 0.031) (Table 5).
Finally, in multivariate analysis, the expression of EGFR at cut
off values of both above5% (P=0.027) and 50% (P= 0.015), the
membranous expression of EGFR (P= 0.007) and EGFR 1+
immunostaining (P= 0.048) were found to remain independent
prognostic factors for poor disease-free survival. Looking at the co-
expression of receptors, only EGFR/HER-4 immunostaining at
above 5% tumour cells remained as an independent prognostic
factor for poor disease-free survival in this study (Table 5). No
significant association was found between HER expression and
overall survival in this study.
Discussion
The aberrant expression of the HER family members and, in
particular, EGFR has been reported in a wide range of human
cancers and has been associated with metastasis and poor
prognosis [6,25,26]. As a result, there has been a substantial
development of molecular therapies targeting EGFR and subse-
quent approval of anti-EGFR mAbs, such as cetuximab and
panitumumab, for the treatment of patients with metastatic
colorectal cancer [2,27]. However, despite extensive studies, there
are currently no reliable markers for predicting the response to
therapy with these EGFR inhibitors [6,28]. In several studies,
Table 3. Co-expression level of HER family members presented as percentage positive tumour cells immunostaining in Dukes’ C
and D colon cancer patients.
Markers Number of positive tumours (%)
.5% cut off .10% cut off .50% cut off
EGFR/HER-2 29 (35) 5 (6) 3 (4)
EGFR/HER-3 20 (24) 15 (18) 3 (4)
EGFR/HER-4 36 (43) 25 (30) 3 (4)
HER-2/HER-3 38 (46) 5 (6) 1 (1)
HER-2/HER-4 63 (76) 10 (12) 7 (8)
HER-3/HER-4 43 (52) 38 (46) 18 (22)
EGFR/HER-2/HER-3 16 (19) 2 (2) 3 (4)
EGFR/HER-2/HER-4 28 (34) 5 (6) 3 (4)
EGFR/HER-3/HER-4 19 (23) 16 (19) 3 (4)
HER-2/HER-3/HER-4 36 (43) 5 (6) 1 (1)
EGFR/HER-2/HER-3/HER-4 15 (18) 2 (2) 0 (0)
doi:10.1371/journal.pone.0091139.t003
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KRAS mutations in patients with colorectal cancer are associated
with resistance to therapy with anti-EGFR antibodies and it is the
only biomarker for predicting patient outcome when treated with
targeted anti-HER therapies in colorectal cancer [29]. However,
despite these advancements, it is clear that not all colorectal cancer
patients with wild-type KRAS would gain benefit from anti-EGFR
mAbs and objective responses have also been reported in patients
with KRAS mutated tumours [30]. One reason for this could be
that KRAS has no direct interaction with antibody binding at the
antigen site and therefore it is prudent to investigate the expression
of other members of the HER family, which have been shown to
activate the downstream pathways, via heterodimerisation and
cross-talk, and drive the tumourigenesis of colorectal cancer in
these patients [17–19].
Several other studies have investigated the expression of the
individual members of the HER family as a prognostic indicator,
Figure 2. The co-expression of all HER family members in a patient with Dukes’ C colon cancer. Co-expression of EGFR, HER-2, HER-3, and
HER-4 in a formalin fixed paraffin embedded tumour sections stained immunohistochemically as described under methods and patients section.
Magnification:6200.
doi:10.1371/journal.pone.0091139.g002
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yet no clear associations have been found between the expression
of HER proteins and prognosis in colorectal cancer patients [31–
37]. The reported expression of EGFR ranges from 8 to 100%,
HER-2 from 1% to 89%, HER-3 from 16 to 89%, and HER-4
from 11 to 81% in colorectal cancer patients [6,14–16,20–22,38].
The wide variation in the reported expression of the HER family
proteins by immunohistochemistry in colorectal cancer may have
contributed to the conflicting data on their prognostic significance
in colorectal cancer [6]. Indeed, factors such as the use of different
antibodies, differences in antigen retrieval techniques, scoring
systems, different patient populations, sample sizes [e.g. tissue
microarrays (TMA)], and different sample numbers could
contribute to the wide variation in the reported expression of
the HER family members in the literature [6,28].
In this study, we investigated the expression of all the members
of the HER family in 86 patients with Dukes’ C and D colon
cancer. Since inconsistencies in the scoring system such as the
usage of different cut off values for HER immunostaining is a
major contributing factor for the wide variation in their reported
expression in the literature, in this study immunostaining were
scored and evaluated using three different cut off values of .5%,
.10%, and .50% (Table 2). Of the 86 cases examined, we found
43%, 77%, 52% and 92% of the cases to have EGFR, HER-2,
HER-3, and HER-4 immunostaining present in .5% of tumour
cells respectively (Figure 1). Herein, while we did not find any
associations between the expression of the HER family members
and overall survival, this is in concordance with other studies in the
literature [6]. Unlike overall survival, in this study the expression
of the EGFR and co-expression of EGFR/HER-4 were associated
with disease-free survival in both univariate and multivariate
analysis (Figure 3 & Table 5). The expression of the EGFR has
been significantly associated with poor disease-free survival and
disease relapse in two other studies. In one study, Galizia et al.
[34] investigated the expression of EGFR in tumour specimens
from 154 Dukes’ A-D colorectal cancer patients and found
membranous expression of the EGFR to be significantly associated
with poor disease-free survival, both in univariate and multivariate
analysis. In another study involving 102 advanced colorectal
cancer patients, 75.5% of the cases were found to express EGFR,
which was significantly associated with disease relapse [39]. In
contrast, Leung et al. [23] in their study of 127 colon cancer
patients using TMA sections, did not find any significant
association between the expression of EGFR, and patient
outcome, but found HER-3 expression to be a significant predictor
of survival outcome. As explained above, differences such as the
use of TMA sections instead of whole tissue blocks, the
heterogeneous nature of tumours, and the use of different cut off
values could be some of the contributing factors for the conflicting
data on the expression and prognostic significance of HER
proteins in colorectal cancer. In addition, as we investigated the
prognostic significance of the HER family members in only 86
patients in this study, this would require further validation in larger
group of colorectal cancer patients.
Table 4. The association between HER family expression and clinicopathological characteristics using the Chi-squared test
(Fisher’s exact test, FET).
Receptors (sub-categories) Number of patients with receptor expression
Clinicopathological parameters P-value (FET)
Age
#70 .70
EGFR (.5%) 6 31 0.022 (0.029)
EGFR/HER-4 (.5%) 6 30 0.031 (0.05)
Tumour Site
Right colon Left colon
EGFR (.5%) 14 23 0.022 (0.028)
EGFR/HER-2 (.5%) 10 19 0.021 (0.024)
EGFR/HER-4 (.5%) 14 22 0.039 (0.048)
EGFR/HER-2/HER-4 (.5%) 10 18 0.036 (0.041)
Dukes’ Stage
C D
HER-4 (.5%) 63 16 0.011 (0.036)
T-stage
T4 ,T4
HER-3 (.10%) 14 25 0.037 (0.045)
EGFR/HER-3 (.10%) 7 8 0.035 (0.05)
HER-3/HER-4 (.10%) 14 24 0.026 (0.042)
Grade
G3 ,G3
HER-4 (1+ intensity) 27 9 0.010 (0.013)
HER-4 (2+ intensity) 24 21 0.013 (0.015)
P-value of #0.05 was considered significant.
doi:10.1371/journal.pone.0091139.t004
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Several studies suggest that the heterodimerisation of HER
family members plays a crucial role in tumourigenesis, and in
particular they may also play an important role in the
development of resistance to therapy in patients with colorectal
cancer [17–19]. However, to date only 4 studies have determined
the expression of all the individual members of the HER family,
but the co-expression levels of all members of the HER family has
not been previously reported in colorectal cancer [20–23]. To our
Figure 3. The association between EGFR and EGFR/HER-4 and disease-free survival in Dukes’ C and D colon cancer patients. Kaplan-
Meier survival curves showing the impact on the disease-free survival of the patients with EGFR expression (A), membranous EGFR expression (B),
EGFR 1+ immunostaining (C) and EGFR/HER-4 co-expression (D). A log-rank test value of P#0.05 was considered statistical significance.
doi:10.1371/journal.pone.0091139.g003
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knowledge, this is the first study to report both the individual
expression and co-expression of all HER family members in
tumour specimens from patients with Dukes’ C and D colon
cancer. Interestingly, considering the cut-off values of 5% and
10% positive tumour cells, we found the co-expression of EGFR/
HER-4 to be significantly associated with disease-free survival in
patients with Dukes’ C and D colon cancer in this study (Table 5).
While some studies report the associations between the co-
expression of HER-2/HER-4 or HER-3/HER-4 and late tumour
stages [21,22], to our knowledge the significant co-expression of
EGFR/HER-4 with poorer disease-free survival in colon cancer
patients has not been previously reported. Our results suggest that
heterodimer formation of EGFR and HER-4 may play an
important role in the tumourigenesis of colon cancer and
contribute to faster disease relapse in these patients. Interestingly,
we found the co-expression of all four members of the HER family
in 18% of the cases examined and 35%, 24% and 43% of the cases
had co-expression of EGFR with HER-2, HER-3 and HER-4
respectively. Consequently, it is essential to investigate whether the
co-expression of other members of the HER family in the EGFR
positive cancers may contribute to resistance, or a poor response to
therapy with the anti-EGFR mAbs cetuximab and panitumumab
in patients with colorectal cancer [6].
In conclusion, the co-expression of all members of the HER
family in a considerable percentage of patients with metastatic
colon cancer patients reported here together with the importance
of heterodimerisation between members of the HER family in the
activation of HER signalling pathways, supports the need for
further studies on their co-expression, prognostic significance and
predictive value for response to therapy with HER inhibitors, in a
larger population of colorectal cancer patients. In particular, such
studies should unravel whether this sub-population of patients may
benefit from therapy with the new generation of pan-HER
inhibitors [40,41].
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